Background
==========

Rheumatoid arthritis \[RA\] is a chronic, systemic autoimmune disorder associated with both genetic and environmental factors. RA affects 1% of the world's population, develops most commonly in adults between 40 -- 70 years old, and occurs more frequently in women than in men \[[@B1]-[@B4]\]. xAlthough the etiology of the disease has not been elucidated fully, the pathogenesis of RA is characterized by the influx of cells from both the innate and the adaptive immune systems \[[@B5]\]. These cells induce increased pro-inflammatory cytokine production, decreased synthesis of anti-inflammatory cytokines, and the subsequent activation and proliferation of synovial fibroblasts (SFs) \[[@B3],[@B4]\]. Rheumatoid arthritis synovial fibroblasts (RASFs) produce additional cytokines, chemokines and matrix-degrading enzymes which ultimately leads to the thickening and progressive destruction of joint membrane, cartilage and bone \[[@B5]-[@B7]\]. Characterization of the cytokine signaling pathways involved in RA has provided a significant opportunity for identifying pro-inflammatory cytokines which can be targeted for novel therapeutic intervention. The development of biological response modifiers (BRMs), particularly the TNF, IL-1, and IL-6 antagonists, have led to major advances in RA therapy \[[@B3],[@B7]\]. However, these agents are not effective in all patients, underscoring the genetic heterogeneity of the disease and the need for the development of additional BRMs \[[@B8]\]. RASFs are intricately involved in the pathogenesis of RA and provide a source for the identification of new genes and pathways that can be targeted for therapeutic intervention.

With the advent of next generation DNA sequencing technologies \[[@B9]\], such as RNA sequencing (RNA-seq), a more comprehensive and accurate transcriptome analysis has become feasible and affordable. In RNA-seq, short fragments of complementary DNA (cDNA) are sequenced (reads) and then mapped onto the reference genome. RNA-seq enables not only the identification of differentially expressed genes, but also the precise quantitative determination of exon and isoform (alternative splicing) expression, along with the characterization of transcription initiation sites (TSSs) and new splicing variants \[[@B10]\]. In the present study, we performed a comprehensive transcriptome analysis of RNA from RASFs from two adult female RA patients and the SF RNA from two healthy female donors, using the RNA-seq technique. We found significant differences in the expression levels of both genes and gene isoforms between normal SFs and RASFs RNA samples. These data provide broader and deeper insights, particularly with respect to isoform expression, into the effect of RA on the transcriptional regulation of synovial fibroblasts and a rich resource for further experimentation into the pathogenesis of the disease.

Results
=======

RNA sequencing
--------------

Human SFs RNAs from two healthy control donors and two patients with RA were purchased from Cell Applications, Inc. (San Diego, CA). Diseased samples were age and sex-matched with normal controls (Additional file [1](#S1){ref-type="supplementary-material"}). Paired-end cDNA libraries for each RNA sample were prepared and sequenced using the Illumina TruSeq RNA Sample Preparation Kit, as outlined previously \[[@B11],[@B12]\].

Quality analysis of RNA-seq data
--------------------------------

Real-time analysis of the sequencing run was performed by the Illumina HiSeq Control Software. Clusters of identical sequences were generated on the Illumina cBot and the number of those clusters was reported, along with the percentage of those clusters passing an internal quality filter. Across the 4 samples, between 433,000 and 482,000 raw clusters were detected, with a median of 446,000 clusters per lane. Between 90.9% and 95.0% of those clusters passed the filter, with a median of 93.2% of the clusters passing the filter. Each lane was aligned in real-time with the phiX genome and between 0.80% and 0.84% of the clusters aligned, with a median of 0.81% aligned. Our control lane of phiX produced 290,000 clusters with 97.9% passing the filter and 99.08% aligning to the phiX genome. All these values were within the recommended limits established by Illumina.

Post-run quality analysis of RNA-seq data was carried out as described by Twine et al. \[[@B13]\]. The total number of reads produced from each sample was between 80,782,262 and 89,757,726, with a mean across all samples of 84,177,268 (Table [1](#T1){ref-type="table"}). The difference in the number of reads between the control samples and the RA samples was not statistically significant (Student's t-test, p=0.27). To assess the quality of the reads, data was pulled from the TopHat log files as well as the output files. Between 0.10% and 0.15% of the reads were removed due to low quality before mapping to the reference genome began. Between 82.8% and 89.1% of the total reads mapped to the human genome. To ensure the uniform coverage across the genome, the data was visualized using a local copy of the Integrative Genomics Viewer. An example of the reads for both normal and RA patient samples mapped against chromosome 1 is shown in Figure [1](#F1){ref-type="fig"}. The average alignment was computed across the genome and those alignment scores were log-transformed (base 2) to better visualize the full range of the data. As expected, no reads mapped to the centromere or areas of the chromosome without genes.

###### 

RNA-seq sequence reads mapping to UCSC Human genome build 19 by TopHat v1.3.0/Bowtie v0.12.7

                                    **WT**                    **RA**                                 
  --------------------------------- ------------ ------------ ------------ ------------ ------------ ------------
                                    **1**        **2**        Average      **1**        **2**        Average
  Total reads                       80,782,262   82,738,536   81,760,399   89,757,726   83,430,548   86,594,137
  Reads removed                     0.10%        0.12%        0.11%        0.15%        0.12%        0.13%
  Read aligned toreference genome   82.8%        84.6%        83.7%        89.1%        87.6%        88.4%

Total reads and the percentage of those reads removed due to low quality and aligned to hg19 by TopHat. TopHat allows two mismatches when aligning to a reference genome.

![**A transcription profile of RNA from control synovial fibroblasts and rheumatoid arthritis fibroblasts for chromosome 1.** The RNA-seq read density plotted along chromosome 1 is shown. Average alignment was computed by igvtools. Each bar represents the log~2~ frequency of reads along the chromosome which range from 0 to 3000 for both control synovial fibroblasts and rheumatoid arthritis fibroblasts.](2045-3701-2-43-1){#F1}

Differentially expressed genes and isoforms
-------------------------------------------

After mapping the sequencing reads to the reference genome with TopHat, transcripts were assembled and their relative expression levels were calculated with Cufflinks in *Fragments Per Kilobase of exon per Million fragments mapped* (FPKM). The sub-program, Cuffdiff was then used to calculate the differential expression on the gene and transcript level, as well as the calculation of alternative promoter usage and alternative splicing. Cufflinks calculates the differential gene expression with the ratio of the RA group to the control group for every gene and transcript along with the statistical significance of the values. Two categories of differential gene/isoform expression were identified. The first category consists of genes/isoforms expressed only in control SFs or only in RASFs. The second category consists of genes/isoforms in which expression of both samples in each group was up-regulated or down-regulated two-fold or greater between control SFs and RASFs.

Overall, there are 12,977 expressed genes in the control SFs and 13,445 expressed genes in the RASFs, which were aligned to the reference genome (Table [2](#T2){ref-type="table"}). There are 214 genes, whose expressions were only detected in the normal SFs, while 682 genes whose expressions were only detected in RASFs. There are 122 up-regulated and 155 down-regulated genes in RASFs with at least two-fold change compared to the SFs (Table [2](#T2){ref-type="table"}). As for known isoforms, there are 20,647 in the normal SFs and 21,102 in RASFs. Among them, there are 526 known isoforms, whose expressions were detected only in the normal SFs, while 981 known isoforms whose expressions were detected only in RASFs. There are 343 up-regulated and 262 down-regulated known isoforms in RASFs by at least two-fold change compared to the SFs (Table [2](#T2){ref-type="table"}). For novel isoforms whose annotations are not known in the current reference gene or transcript database, there are 42,124 expressed in the normal SFs and 42,171 expressed in RASFs. Among them, there are 105 novel isoforms whose expressions were only detected in the normal SFs, while 152 novel isoforms were only detected in RASFs. There are 561 up-regulated and 520 down-regulated novel isoforms in RASFs by at least two-fold change compared to the SFs (Table [2](#T2){ref-type="table"}).

###### 

Gene/isoform expression summary

                                                  **Genes**            
  ----------------------------------------------- -------------------- -------------
                                                  Control              RA Patients
  Total Genes Expressed                           12,977               13,445
  Control Only                                    214                   
  RA Patients Only                                                     682
  Up-regulated (2-fold or greater difference)                          122
  Down-regulated (2-fold or greater difference)                        155
                                                  **Known Isoforms**   
                                                  Control              RA Patients
  Total Known Isoforms Expressed                  20,647               21,102
  Control Only                                    526                   
  RA Patients Only                                                     981
  Up-regulated (2-fold or greater difference)                          343
  Down-regulated (2-fold or greater difference)                        262
                                                  **Novel Isoforms**   
                                                  Control              RA Patients
  Total Novel Isoforms Expressed                  42,124               42,171
  Control Only                                    105                   
  RA Patients Only                                                     152
  Up-regulated (2-fold or greater difference)                          561
  Down-regulated (2-fold or greater difference)                        520

Genes, known isoforms and novel isoforms expressed in control synovial fibroblasts and synovial fibroblasts from patients with rheumatoid arthritis. Expression determined by Cufflinks, after normalization to a panel of housekeeping genes. The fold change is the ratio of RA FPKM to WT FPKM.

Genes expressed only in control SFs or only in RASFs
----------------------------------------------------

The top 10 up- and down-regulated genes expressed only in control SFs or only in RASFs are presented in Table [3](#T3){ref-type="table"}. An expanded list of the top 50 genes expressed only in either control SFs or in RASFs is presented in Additional file [2](#S2){ref-type="supplementary-material"}. Analysis of the genes expressed only in RASF reveals that nine of the top ten genes, including the major histocompatibility complex (MHC) genes HLA-A. --B, -C, and --E, are located on chromosome 6 (Table [3](#T3){ref-type="table"}). Remarkably, 36 of the top 50 genes (Additional file [2](#S2){ref-type="supplementary-material"}) expressed only in RASFs are located on chromosome 6. The MHC, particularly the HLA-DRB1 alleles are strongly associated with RA \[[@B14]-[@B16]\]. A recent study by Plenge et al. has also identified associations of alleles lying outside the MHC on chromsome 6 with RA \[[@B17]\]. Our observation that the CLIC1 gene (chloride intracellular protein) is expressed in RASFs correlates with the finding that CLIC1(-/-) mice were protected from development of serum transfer induced K/BxN arthritis \[[@B18]\]. Two genes, the high mobility group box 1 (HMGA1) and the latent transforming growth factor beta binding protein 1 (LTBP1) have been reported to be elevated in RA \[[@B19],[@B20]\] however they are not expressed in the RASFs examined in this study (Table [3](#T3){ref-type="table"}). Interestingly, HMGA1 is the only gene on chromosome 6 in the list of top 50 genes expressed in normal SFs but not expressed in RASFs (Additional file [2](#S2){ref-type="supplementary-material"}). The CD59 complement regulatory protein (CD59) is not expressed in RASFs in this study. This observation supports the finding that CD59 is protective as CD59 (-/-) knockout mice present with more severe symptoms in the murine antigen-induced arthritis model \[[@B21]\]. An automated literature search using PubMatrix \[[@B22]\] reveals that eleven of the twenty genes listed in Table [3](#T3){ref-type="table"} have not yet been identified to be associated with RA (Additional file [3](#S3){ref-type="supplementary-material"}). These genes, which include chromosome 6 open reading frame 48 (C6orf48), the scavenger receptor class A, member 5 (SCARA5), CutA divalent cation tolerance homolog (CUTA), Leucine rich repeat containing 59 (LRRC59), and the protein phosphatase 1, regulatory (inhibitor) subunit 14A (PPP1R14A), may provide additional therapeutic targets. These potential targets include characterized genes, like the iron receptor SCARA5 \[[@B23]\] and genes, such as C6orf48, that have not yet been well-studied. CutA, which is up-regulated in RASFs, interacts with BACE1 to regulate B-cleavage of the B-amyloid protein (APP) \[[@B24]\]. CutA may play a role in the pathogenesis of Alzheimer's, however, its role in rheumatoid arthritis remains to be elucidated. LRRC59 is required for the nuclear transport of the fibroblast growth factor 1 (FGF1) \[[@B25]\]. The affect on FGF1 function resulting from decreased LRRC59 expression in RASFs warrants further investigation. PPP1R14A, which inhibits protein phosphatase 1 activity, is not expressed in RASFs compared to normal SFs, suggesting that PP1 activity will increase dramatically in RASFs. PP1 controls the Akt signal transduction pathway to regulate cell growth, cell survival, and cell differentiation \[[@B26]\].

###### 

Top ten up- and down- regulated genes expressed only in normal synovial RNA or only in rheumatoid arthritis synovial RNA

  **Gene**   **Description**                                             **Chr**   **RA FPKM**   **RA2 FPKM**   **WT1 FPKM**   **WT2 FPKM**   **Avg.RA**   **Avg.WT**   **Ensembl gene ID**
  ---------- ----------------------------------------------------------- --------- ------------- -------------- -------------- -------------- ------------ ------------ ---------------------
  HLA-B      Major histocompatibility complex, class 1, B                chr6      704.3         728.3          \--            \--            716.3        \--          ENSG00000228964
  HLA-A      Major histocompatibility complex, class 1, A                chr6      778.2         585.6          \--            \--            681.9        \--          ENSG00000223980
  HLA-C      Major histocompatibility complex, class 1, C                chr6      534.8         452.1          \--            \--            493.5        \--          ENSG00000206435
  TUBB       Tubulin, beta class I                                       chr6      405.3         416.7          \--            \--            411          \--          ENSG00000232421
  CLIC1      Chloride intracellular channel 1                            chr6      350.5         369.6          \--            \--            360          \--          ENSG00000223639
  RPS18      Ribosomal Protein S18                                       chr6      260.4         269.1          \--            \--            264.8        \--          ENSG00000227794
  HLA-E      Major histocompatibility complex, class 1, E                chr6      243.5         260.2          \--            \--            251.9        \--          ENSG00000230254
  C6orf48    Chromosome 6 open reading frame 48                          chr6      119.5         225.8          \--            \--            172.6        \--          ENSG00000206380
  SCARA5     Scavenger receptor class A, member 5                        chr8      11.36         316            \--            \--            163.7        \--          ENSG00000168079
  CUTA       CutA divalent cation tolerance homolog                      chr6      168.7         133.7          \--            \--            151.2        \--          ENSG00000226492
  ACTG2      Actin, gamma 2, smooth muscle, enteric                      chr2      \--           \--            1087.76        2.58           \--          545.17       ENSG00000163017
  RPS24      Ribosomal Protein S24                                       chr10     \--           \--            407.72         429.08         \--          418.40       ENSG00000138326
  PSAP       Prosaposin                                                  chr10     \--           \--            236.86         519.83         \--          378.35       ENSG00000197746
  HMGA1      High mobility group box 1                                   chr6:     \--           \--            139.35         265.81         \--          202.58       ENSG00000189403
  CD59       CD59 molecule, complement regulatory protein                chr11     \--           \--            111.47         149.28         \--          130.38       ENSG00000085063
  LRRC59     Leucine rich repeat containing 59                           chr17     \--           \--            116.95         88.57          \--          102.76       ENSG00000108829
  PPP1R14A   Protein phosphatase 1, regulatory (inhibitor) subunit 14A   chr19     \--           \--            142.49         1.10           \--          71.79        ENSG00000167641
  LTBP1      Latent transforming growth factor beta binding protein 1    chr2      \--           \--            54.38          66.08          \--          60.23        ENSG00000049323
  SNHG6      Small nucleolar RNA host gene 6                             chr8      \--           \--            46.68          65.62          \--          56.15        ENSG00000245910
  HNRNPC     Heterogeneous nuclear ribonucleoprotein C (C1/C2)           chr14     \--           \--            52.08          58.46          \--          55.27        ENSG00000092199

Genes which were differentially expressed as determined by Cufflinks, after normalization to a panel of housekeeping genes.

The genes were ranked by FPKM and the 10 with the highest or lowest values are listed here.

Genes differentially expressed two-fold or greater between control SFs and RASFs
--------------------------------------------------------------------------------

The top 10 up- and down-regulated genes, along with the expanded top 50 list, in which expression of both samples in each group was up-regulated or down-regulated two-fold or greater between control SFs and RASFs are presented in Table [4](#T4){ref-type="table"} and in Additional file [4](#S4){ref-type="supplementary-material"}, respectively. Three genes in the top 10 up-regulated list have been associated with rheumatoid arthritis (Additional file [3](#S3){ref-type="supplementary-material"}). Interleukin 26 (IL26) is up-regulated (80.8-fold) in RASFs compared to SFs. Corvaisier et al. has demonstrated that IL26 is over-expressed in arthritis and induces inflammatory cytokine production \[[@B27]\]. The v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) (MAFB) gene is up-regulated (16.2-fold) in RASFs. Liu et al. identified polymorphisms in the MAFB gene associated with altered response to anti-TNF treatment in patients with RA \[[@B28]\]. Expression of the adrenergic, alpha-2A-, receptor (ADRA2A) increased 14.4-fold in RASFs. The adrenergic, alpha-2A-, receptor may play a critical role in the proliferation and differentiation of synoviocytes \[[@B29]\]. Although thrombospondin 4 (THSB4) has not yet been associated with arthritis (Additional file [3](#S3){ref-type="supplementary-material"}), thrombospondin 1 (THBS1) is over-expressed in RA tissue \[[@B30]\]. Thrombospondin 1 and 4 are extracellular matrix remodeling proteins that have been associated with increased inflammation in coronary artery disease (CAD) \[[@B30],[@B31]\], and thus may provide a link between RA and CAD. Like THBS4, the remaining six genes up-regulated in RASFs (Table [4](#T4){ref-type="table"}) have not yet been associated with RA but provide potential for further investigation. The solute carrier family members, SLC2A5, SLC14A1, and SLC12A8 are over-expressed in RASFs suggesting alterations in cellular metabolism. Complement Factor 1 (CF1) may represent a new target as the complement system plays a major role in the pathogenesis of rheumatoid disease \[[@B32]\]. Expression of the plasminogen activator inhibitor gene, serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2) is decreased (-79.1-fold) in RASFs compared to control SFs (Table [4](#T4){ref-type="table"}). The plasminogen activation pathway is dysregulated in arthritis \[[@B33]\]. Aquoporin 1 (AQP1) expression has been shown to be up-regulated in the synovium from RA patients \[[@B34]\], but is down-regulated (-44.3-fold) in our samples. The coagulation factor X (F10), which may contribute to tissue injury and remodeling \[[@B35]\], is down-regulated (-27.5 fold). The hedgehog interacting protein (HHIP) inhibits the sonic hedgehog (SSH) signaling pathway. Inactivation of SSH inhibitor smoothened (Smo) blocks sonic hedgehog signaling and prevents osteophyte formation in the murine serum transfer arthritis model \[[@B36]\]. Thus, the decrease (-26.6-fold) in HHIP expression observed in RASFs in this study may result in increased SSH activity resulting in advanced osteophyte formation.

###### 

Top ten up- and down- regulated genes expressed in rheumatoid arthritis synovial RNA

  **Gene**     **Description**                                                          **Chr**   **RAFPKM**   **RA2FPKM**   **WT2FPKM**   **WT2FPKM**   **Avg. RA**   **Avg. WT**   **Fold change**   **Ensembl gene ID**
  ------------ ------------------------------------------------------------------------ --------- ------------ ------------- ------------- ------------- ------------- ------------- ----------------- ---------------------
  IL26         interleukin 26 solute carrier family 2 (facilitated                      chr12     17.913       1.927         0.101         0.144         9.920         0.123         80.83             ENSG00000111536
  SLC2A5       glucose/fructose transporter), member 5                                  chr1      65.268       21.844        0.340         3.851         43.556        2.096         20.79             ENSG00000142583
  PLXDC2       plexin domain containing 2 v-maf musculoaponeurotic                      chr10     9.222        2.316         0.098         0.573         5.769         0.335         17.21             ENSG00000120594
  MAFB         fibrosarcoma oncogene homolog B (avian) solute carrier family 14 (urea   chr20     37.177       6.679         0.605         2.096         21.928        1.351         16.24             ENSG00000204103
  SLC14A1      transporter), member 1 (Kidd blood group                                 chr18     6.188        2.096         0.360         0.177         4.142         0.269         15.41             ENSG00000141469
  ADRA2A       adrenergic, alpha-2A-, receptor                                          chr10     4.373        10.666        0.899         0.145         7.519         0.522         14.42             ENSG00000150594
  MAN1C1       mannosidase, alpha, class 1C, member 1                                   chr1      16.774       24.3346       0.65654       2.7991        20.554        1.728         11.90             ENSG00000117643
  CFI          complement factor I solute carrier family 12                             chr4      21.803       28.7589       0.10437       4.3263        25.281        2.215         11.41             ENSG00000205403
  SLC12A8      (potassium/chloride transporters), member 8                              chr3      7.442        15.2539       0.62851       1.4395        11.348        1.034         10.97             ENSG00000221955
  THBS4        thrombospondin 4                                                         chr5      5.8622       7.09226       0.05843       1.2202        6.477         0.639         10.13             ENSG00000113296
  SERPINB2     serpin peptidase inhibitor, clade B (ovalbumin), member 2                chr18     0.236        0.095         16.207        10.030        0.166         13.118        −79.11            ENSG00000197632
  AQP1         aquaporin 1 (Colton blood group)                                         chr7      5.675        3.860         396.183       25.802        4.768         210.992       −44.26            ENSG00000240583
  APOBEC3B     apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B      chr22     0.0775       0.23398       2.59902       7.4102        0.156         5.005         −32.13            ENSG00000179750
  NEFM         neurofilament, medium polypeptide                                        chr8      0.0592       0.07122       3.69528       0.2014        0.065         1.948         −29.87            ENSG00000104722
  CCDC3        coiled-coil domain containing 3                                          chr10     0.1241       0.09255       4.48673       1.7074        0.108         3.097         −28.59            ENSG00000151468
  F10          coagulation factor X                                                     chr13     0.197        0.21727       8.44739       2.9581        0.207         5.703         −27.53            ENSG00000126218
  HHIP         hedgehog interacting protein                                             chr4      0.073        0.26532       7.88577       1.1075        0.169         4.497         −26.58            ENSG00000164161
  ARL2-SNX15   \-                                                                       chr11     0.361        0.39062       8.29552       11.168        0.376         9.732         −25.90            \-
  HES4         hairy and enhancer of split 4                                            chr1      0.3015       0.46829       16.2396       1.0894        0.385         8.664         −22.51            ENSG00000188290
  GPAT2        glycerol-3-phosphate acyltransferase 2, mitochondrial                    chr2      0.5547       0.36585       17.6005       3.0486        0.460         10.325        −22.43            ENSG00000186281

Genes which were differentially expressed as determined by Cufflinks, after normalization to a panel of housekeeping genes. The fold change is the ratio of RASF FPKM to control FPKM. Genes with a fold change of 1.2-fold or greater were defined as significant. The genes were ranked on their fold change and the 10 with the highest or lowest fold changes are listed here.

Known isoforms expressed only in control SFs or only in RASFs
-------------------------------------------------------------

The top 10 isoforms expressed only in control SFs or only in RASFs are presented in Table [5](#T5){ref-type="table"}. An expanded list of the top 50 up- and down-regulated known isoforms expressed only in either control SFs or in RASFs is presented in Additional file [5](#S5){ref-type="supplementary-material"}. The known isoforms identified in Table [5](#T5){ref-type="table"} correlate with the genes expressed only in control SFs or only in RASFs (Table [3](#T3){ref-type="table"} and Additional file [2](#S2){ref-type="supplementary-material"}). Single isoforms were detected for SCARA5, PLA2G2A, SPCS1, CITED2, IL13RA2, SLP1, FAM20A, NUMA1, PSAP, LRRC59, PPP1R14A, and SNHG6. Two isoforms were identified for PRG4, ACTG2, and CD59, while five and six isoforms exist for RPS24 and HMG1A, respectively (Table [5](#T5){ref-type="table"} and Additional file [5](#S5){ref-type="supplementary-material"}).

###### 

Top ten up- and down- regulated isoforms expressed only in normal synovial RNA or only in rheumatoid arthritis synovial RNA

  **Gene**   **Description**                                             **Locus**   **Length**   **RA1FPKM**   **RA2FPKM**   **WT1FPKM**   **WT2FPKM**   **Avg. RA**   **Avg. WT**   **Ensembl gene ID**
  ---------- ----------------------------------------------------------- ----------- ------------ ------------- ------------- ------------- ------------- ------------- ------------- ---------------------
  SCARA5     Scavenger receptor class A, member 5                        chr8        4151         11.36         353.51        \--           \--           182.43        \--           ENSG00000168079
  PLA2G2A    Phopholipase A2, group IIA                                  chr1        969          3.81          264.84        \--           \--           134.33        \--           ENSG00000188257
  SPCS1      Signal peptidase complex subunit 1 homolog                  chr3        1084         81.32         112.54        \--           \--           96.93         \--           ENSG00000114902
  CITED2     Cbp/p300-interacting transactivator, 2                      chr6        1929         69.03         119.73        \--           \--           94.38         \--           ENSG00000164442
  IL13RA2    Interleukin 13 receptor, alpha 2                            chrX        1373         9.94          90.27         \--           \--           50.10         \--           ENSG00000123496
  SLPI       Secretory leukocyte peptidase inhibitor                     chr20       598          1.36          98.75         \--           \--           50.06         \--           ENSG00000124107
  KYNU       Kynureninase                                                chr2        1672         16.46         79.31         \--           \--           47.88         \--           ENSG00000115919
  FAM20A     Family with sequence similarity 20, member A                chr17       4275         28.98         60.54         \--           \--           44.76         \--           ENSG00000108950
  NUMA1      Nuclear mitotic apparatus protein 1                         chr11       7182         40.51         45.42         \--           \--           42.96         \--           ENSG00000137497
  PRG4       Proteoglycan 4                                              chr1        4765         1.27          81.59         \--           \--           41.43         \--           ENSG00000116690
  ACTG2      Actin, gamma 2, smooth muscle, enteric                      chr2        1331         \--           \--           1046.45       2.16          \--           524.30        ENSG00000163017
  PSAP       Prosaposin                                                  chr10       2822         \--           \--           234.56        510.86        \--           372.71        ENSG00000197746
  RPS24      Ribosomal Protein S24                                       chr10       655          \--           \--           149.70        298.29        \--           224.00        ENSG00000138326
  LRRC59     Leucine rich repeat containing 59                           chr17       2915         \--           \--           116.95        88.57         \--           102.76        ENSG00000108829
  HMGA1      High mobility group box 1                                   chr6        1846         \--           \--           44.78         99.59         \--           72.19         ENSG00000189403
  CD59       CD59 molecule, complement regulatory protein                chr11       7619         \--           \--           68.61         75.31         \--           71.96         ENSG00000085063
  PPP1R14A   Protein phosphatase 1, regulatory (inhibitor) subunit 14A   chr19       718          \--           \--           142.49        1.10          \--           71.79         ENSG00000167641
  HMGA1      High mobility group box 1                                   chr6        1993         \--           \--           43.81         93.26         \--           68.54         ENSG00000189403
  RPS24      Ribosomal Protein S24                                       chr10       633          \--           \--           80.53         47.31         \--           63.92         ENSG00000138326
  SNHG6      Small nucleolar RNA host gene 6                             chr8        472          \--           \--           46.68         65.62         \--           56.15         ENSG00000245910

Isoforms which were differentially expressed as determined by Cufflinks, after normalization to a panel of housekeeping genes.

The isoforms were ranked by FPKM and the 10 with the highest or lowest values are listed here.

Known isoforms differentially expressed two-fold or greater between control SFs and RASFs
-----------------------------------------------------------------------------------------

The top 10 up- and down-regulated known isoforms, along with the expanded top 50 list, in which expression of both samples in each group was up-regulated or down-regulated two-fold or greater between control SFs and RASFs are presented in Table [6](#T6){ref-type="table"} and in Additional file [6](#S6){ref-type="supplementary-material"}, respectively. Thirteen of the known isoforms identified in Table [6](#T6){ref-type="table"} can be found in the top 50 up-regulated and down-regulated genes presented in Table [4](#T4){ref-type="table"} and Additional file [4](#S4){ref-type="supplementary-material"}. A single isoform of IL26 is expressed 80.8-fold and correlates with the expression (80.8-fold) of the IL26 gene in RASFs. Seven known isoforms (ILI27, DHPS, BLCAP, LYNX1, C5orf13, APLP2, and CSRP1) are not represented in the top 50 regulated genes. One reason for this observation is differential isoform expression, as demonstrated by the two isoforms of Interferon, alpha-inducible protein 27 (ILI27). One ILI27 isoform is up-regulated 35.8-fold and one is down-regulated 216.8-fold. Two known isoforms were also identified for GCNT1, SLC2A5 and C5orf13 in the top 50 list.

###### 

Top ten up- and down- regulated known isoforms expressed in rheumatoid arthritis synovial RNA

  **Gene**   **Description**                                                                **Locus**   **Length**   **RA1FPKM**   **RA2FPKM**   **WT1FPKM**   **WT2FPKM**   **Avg. RA**   **Avg. WT**   **Fold change**   **Ensembl gene ID**
  ---------- ------------------------------------------------------------------------------ ----------- ------------ ------------- ------------- ------------- ------------- ------------- ------------- ----------------- ---------------------
  IL26       interleukin 26                                                                 chr12       1047.00      17.91         1.93          0.10          0.14          9.92          0.12          80.83             ENSG00000111536
  GCNT1      glucosaminyl (N-acetyl) transferase 1, core 2                                  chr9        5478.00      3.99          3.35          0.08          0.05          3.67          0.07          55.82             ENSG00000187210
  IFI27      interferon, alpha-inducible protein 27                                         chr14       652.00       272.04        223.93        5.09          8.77          247.99        6.93          35.79             ENSG00000165949
  GCNT1      glucosaminyl (N-acetyl) transferase 1, core 2                                  chr9        5596.00      3.81          2.20          0.06          0.13          3.01          0.09          32.54             ENSG00000187210
  IGFBP3     insulin-like growth factor binding protein 3                                   chr7        2631.00      123.09        213.34        2.30          8.88          168.22        5.59          30.09             ENSG00000146674
  DHPS       deoxyhypusine synthase                                                         chr19       1184.00      12.04         2.92          0.40          0.14          7.48          0.27          27.42             ENSG00000095059
  BLCAP      bladder cancer associated protein                                              chr20       2073.00      9.25          2.16          0.20          0.32          5.70          0.26          22.14             ENSG00000166619
  SLC2A5     solute carrier family 2 (facilitated glucose/fructose transporter), member 5   chr1        2438.00      62.93         20.78         0.21          3.63          41.85         1.92          21.79             ENSG00000142583
  SLC12A8    solute carrier family 12 (potassium/chloride transporters), member 8           chr3        3447.00      6.34          16.64         0.32          0.73          11.49         0.52          22.01             ENSG00000221955
  LYNX1      Ly6/neurotoxin 1                                                               chr8        1290.00      6.07          3.23          0.39          0.06          4.65          0.23          20.48             ENSG00000180155
  C5orf13    chromosome 5 open reading frame 13                                             chr5        1996.00      0.32          0.71          303.46        6.35          0.52          154.91        −300.00           ENSG00000134986
  IFI27      interferon, alpha-inducible protein 27                                         chr14       648.00       0.40          1.10          5.62          318.85        0.75          162.23        −216.80           ENSG00000165949
  C5orf13    chromosome 5 open reading frame 13                                             chr5        2068.00      0.14          0.19          40.42         1.50          0.16          20.96         −127.90           ENSG00000134986
  APLP2      amyloid beta (A4) precursor-like protein 2                                     chr11       3274.00      0.06          0.23          5.27          15.27         0.14          10.27         −71.07            ENSG00000084234
  CSRP1      cysteine and glycine-rich protein 1                                            chr1        1938.00      0.20          0.41          34.33         3.74          0.31          19.03         −61.54            ENSG00000159176
  AQP1       aquaporin 1                                                                    chr7        2807.00      4.71          2.55          390.29        23.23         3.63          206.76        −56.95            ENSG00000240583
  PARP2      poly (ADP-ribose) polymerase 2                                                 chr14       1887.00      0.10          0.19          2.43          6.85          0.14          4.64          −32.85            ENSG00000129484
  APOBEC3B   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B            chr22       1536.00      0.08          0.26          2.60          7.41          0.17          5.00          −29.50            ENSG00000179750
  CCDC3      coiled-coil domain containing 3                                                chr10       2738.00      0.12          0.10          4.49          1.71          0.11          3.10          −27.21            ENSG00000151468
  MTIF3      mitochondrial translational initiation factor 3                                chr13       1098.00      0.14          0.22          3.98          5.73          0.18          4.85          −26.92            ENSG00000122033

Isoforms which were differentially expressed as determined by Cufflinks, after normalization to a panel of housekeeping genes. The fold change is the ratio of RASF FPKM to control FPKM. Isoforms with a fold change of 1.2-fold or greater were defined as significant. The isoforms were ranked on their fold change and the 10 with the highest or lowest fold changes are listed here.

Novel isoforms expressed only in control SFs or only in RASFs
-------------------------------------------------------------

The top 10 up- and down-regulated novel isoforms expressed only in control SFs or only in RASFs are presented in Table [7](#T7){ref-type="table"}. An expanded list of the top 50 up- and down-regulated known isoforms expressed only in either control SFs or in RASFs is presented in Additional file [7](#S7){ref-type="supplementary-material"}. The list of the top 10 up-regulated novel isoforms includes transcripts for four unannotated genomic regions. The top 50 novel isoforms contains 21 transcripts from unannotated genomic regions. The list of top 10 down-regulated novel isoforms is divided into nine isoforms from annotated genes, including a novel transcript for HHIP, and one down-regulated novel isoform. There are transcripts for fourteen unannotated genomic regions in the top 50 down-regulated novel isoforms.

###### 

Top ten up- and down- regulated novel isoforms expressed only in normal synovial RNA or rheumatoid arthritis synovial RNA

  **Gene**   **Description**                                         **Coordinates**             **Length**   **FPKM Wildtype**   **FPKM RA**   **Ensembl gene ID**
  ---------- ------------------------------------------------------- --------------------------- ------------ ------------------- ------------- ---------------------
  GIPC1      GIPC PDZ domain containing family. Member 1             chr19:14588570-14606944     1650         \--                 8.09135       ENSG00000123159
  MPPE1      Metallophosphoesterase 1                                chr18:11883385-11908455     1973         \--                 5.66007       ENSG00000154889
  \-         NA                                                      chr11:69066649-69184402     410          \--                 5.19725       NA
  EPB41L2    Erythrocyte membrane protein band 4.1-like 2            chr6:131160487-131384462    3393         \--                 4.45046       ENSG00000079819
  MRPL14     Mitochondrial ribosomal protein L14                     chr6:44072507-44123256      658          \--                 4.29538       ENSG00000180992
  PPIEL      Peptidylprolyl isomerase E-like pseudogene              chr1:39987953-40025316      509          \--                 4.21536       ENSG00000243970
  \-         NA                                                      chr6:166822859-167041186    3525         \--                 3.83632       NA
  \-         NA                                                      chr21:39607975-39679370     1369         \--                 3.3631        NA
  FAM101A    Family with sequence similarity 101. member A           chr12:124774147-124800566   2242         \--                 3.16322       ENSG00000178882
  \-         NA                                                      chr4:39454172-39460535      666          \--                 3.12642       NA
  \-         NA                                                      chr20:30432079-30433458     1379         18.1953             \--           NA
  GPAT2      Glycerol-3-phosphate acyltransferase 2, mitochondrial   chr2:96687342-96700658      2732         6.12103             \--           ENSG00000186281
  PCDHGC5    Protocadherin gamma subfamily C, 5                      chr5:140746308-140914003    4930         6.08509             \--           ENSG00000240764
  RSAD2      Radical S-adenosyl methionine domain containing 2       chr2:6988770-7038095        5210         4.87066             \--           ENSG00000134321
  HEYL       Hairy/enhancer of split related with YRPW motif-like    chr1:40089102-40105348      3872         4.34476             \--           ENSG00000163909
  GPR107     G protein-coupled receptor 107                          chr9:132815745-132902440    3463         4.15184             \--           ENSG00000148358
  GOLGA2     Golgin A2                                               chr9:131018105-131038268    3014         2.8846              \--           ENSG00000167110
  HHIP       Hedgehog interacting protein                            chr4:145567142-145660251    2628         2.57248             \--           ENSG00000164161
  ITIH3      Inter-alpha-trypsin inhibitor heavy chain 3             chr3:52828743-52838029      1944         2.20862             \--           ENSG00000162267
  HEATR5A    HEAT repeat containing 5A                               chr14:31757730-31889797     6427         2.17675             \--           ENSG00000129493

Novel isoforms which were differentially expressed as determined by CuffDiff after Benjamini-Hochberg correction. The isoforms were ranked by FPKM and the 10 with the highest or lowest fold changes are listed here.

Novel isoforms differentially expressed two-fold or greater between control SFs and RASFs
-----------------------------------------------------------------------------------------

The top 10 up- and down-regulated novel isoforms, along with the expanded top 50 list, in which expression of both samples in each group was up-regulated or down-regulated two-fold or greater between control SFs and RASFs are presented in Table [8](#T8){ref-type="table"} and in Additional file [8](#S8){ref-type="supplementary-material"}, respectively. A transcript of Fibrillin 1 (FBN1) is the top up-regulated novel isoform. Of note, a mutation in FBN1, which encodes an extracellular matrix glycoprotein, has been associated with the coexistence of Marfan's Syndrome and ankylosing spondylitis \[[@B37]\]. Novel isoforms from three unannotated regions of the genome were identified in the top 10 up-regulated novel isoforms. A total of 13 novel isoforms identified within unannotated regions of the genome were up-regulated in RASFs compared to SFs (Additional file [8](#S8){ref-type="supplementary-material"}). The list of top 10 down-regulated novel isoforms is divided into nine isoforms from annotated genes and one down-regulated novel isoform. A total of 10 novel isoforms within unannotated regions of the genome were down-regulated in RASFs compared to SFs. Interestingly, there are two novel transcripts for both HLA-DRB1 and SLC2A5 identified in this study (Additional file [8](#S8){ref-type="supplementary-material"}).

###### 

Top ten up- and down- regulated novel isoforms expressed in rheumatoid arthritis synovial RNA

  **Gene**   **Description**                                                                          **Coordinates**             **Length**   **FPKM Wildtype**   **FPKM RA**   **Fold change**   **Ensembl gene ID**
  ---------- ---------------------------------------------------------------------------------------- --------------------------- ------------ ------------------- ------------- ----------------- ---------------------
  FBN1       fibrillin 1                                                                              chr15:48700502-48944261     3642         0.35665             122.625       343.82            ENSG00000166147
  TNXB       tenascin XB                                                                              chr6:31913771-32077409      10005        0.0711364           9.52612       133.91            ENSG00000168477
  VCAN       versican                                                                                 chr5:82767225-82878111      7388         0.145287            17.706        121.87            ENSG00000038427
  LRP1       low density lipoprotein receptor-related protein 1                                       chr12:57522228-57607140     6609         0.223758            19.9154       89.00             ENSG00000123384
  DPYSL2     dihydropyrimidinase-like 2                                                               chr8:26435420-26515693      3416         0.287829            23.9348       83.16             ENSG00000092964
  \-         Genes nearby:FAM198B: family with sequence similarity 198, member B                      chr4:159045731-159093718    1964         0.064901            5.20752       80.24             ENSG00000164125
  \-         Genes nearby:TGFBR3: transforming growth factor, beta receptor III                       chr1:92145899-92351836      1323         0.137404            11.0015       80.07             ENSG00000069702
  ALDH1L2    aldehyde dehydrogenase 1 family, member L2                                               chr12:105413561-105478341   4568         0.0522639           3.45172       66.04             ENSG00000136010
  \-         NA                                                                                       chr14:74964883-75079368     2880         0.114262            6.82866       59.76             NA
             Genes nearby: ISCA2: iron-sulfur cluster assembly 2 homolog                                                                                                                           ENSG00000165898
  SNED1      LTBP2: latent transforming growth factor beta binding protein 2                          chr2:241936998-242041710    8107         0.15755             9.34599       59.32             ENSG00000119681
  TINAGL1    tubulointerstitial nephritis antigen-like 1                                              chr1:32041807-32053290      995          129.883             0.462813      −280.64           ENSG00000142910
  TPM2       tropomyosin 2 (beta)                                                                     chr9:35681989-35690053      1083         78.6638             0.329924      −238.43           ENSG00000198467
  MT2A       metallothionein 2A                                                                       chr16:56642376-56692994     248          701.232             5.35657       −130.91           ENSG00000125148
  FSTL1      follistatin-like 1                                                                       chr3:120113060-120169918    1640         10.7318             0.0822263     −130.52           ENSG00000163430
  ITPRIP     inositol 1,4,5-trisphosphate receptor interacting protein                                chr10:106069730-106098576   6523         18.5495             0.146115      −126.95           ENSG00000148841
  \-         NA                                                                                       chr13:41958154-41958844     690          51.6499             0.522452      −98.86            NA
  SPTBN1     spectrin, beta, non-erythrocytic 1                                                       chr2:54683453-54898583      7086         12.396              0.126624      −97.90            ENSG00000115306
  HLA-DRB1   major histocompatibility complex, class II, DR beta 5                                    chr6:32441211-32557589      513          12.6351             0.129095      −97.87            ENSG00000198502
  SEMA3F     sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F   chr3:50192454-50226507      3394         6.92733             0.0764133     −90.66            ENSG00000001617
  CNN1       calponin 1, basic, smooth muscle                                                         chr19:11649578-11661139     659          67.4653             0.799449      −84.39            ENSG00000130176

Novel isoforms which were differentially expressed as determined by CuffDiff after Benjamini-Hochberg correction. The fold change is the ratio of RASF FPKM to control FPKM. Novel isoforms with a fold change of 1.2-fold or greater were defined as significant. The isoforms were ranked on their fold change and the 10 with the highest or lowest fold changes are listed here.

Network and pathway analyses of differentially expressed genes
--------------------------------------------------------------

To identify network and pathway connectivity, the differentially expressed gene lists of a two-fold or greater change in RASFs compared to SFs were submitted to Ingenuity Pathway Analysis (IPA) v9.0-3211 (Ingenuity Systems, Inc., Redwood City, CA), as described in the Material and Methods section. The networks affected by up-regulated genes and isoforms in RASFs compared to normal SFs are listed in Table [9](#T9){ref-type="table"}. Consistent with the knowledge that RA is an immune disorder, the top network predicted to be affected by the up-regulated genes was *Inflammatory Response, Immunological Disease, Cell Death*, while the top network predicted to be affected by the up-regulated isoforms was *Inflammatory Response, Cellular Movement, Cell-To-Cell Signaling and Interaction*. The pathways affected by up-regulated genes and/or isoforms correlated with the pathways predicted to be affected by down-regulated gene expression and changes in isoform expression (Table [10](#T10){ref-type="table"}). The top networks affected by down-regulated genes and isoforms in RASFs compared to normal SFs are *Cellular Movement, Cell Death, and Tissue Development* and *Cellular Growth and Proliferation, Cell Death, Cellular Movement*, respectively.

###### 

Top networks affected by up-regulated genes/isoforms in rheumatoid arthritis synovial RNA

                                                                                                                 **Up-regulated genes**   
  -------------------------------------------------------------------------------------------------------------- ------------------------ -------
  Top Functions                                                                                                  Score                    Genes
  Inflammatory Response, Immunological Disease, Cell Death                                                       68                       58
  Cell Morphology, Tissue Development, Cell Death                                                                30                       36
  Cell-To-Cell Signaling and Interaction, Hematological System                                                                             
  Development and Function, Immune Cell Trafficking                                                              25                       32
  Inflammatory Response, Infectious Disease, Immunological Disease                                               23                       31
  Cellular Development, Cancer, Developmental Disorder                                                           22                       30
  Inflammatory Response, Cellular Development, Cell Death                                                        22                       30
  Cell Death, Hematological System Development and Function, Tissue Morphology                                   22                       30
                                                                                                                 Up-Regulated Isoforms    
  Top Functions                                                                                                  Score                    Genes
  Inflammatory Response, Cellular Movement, Cell-To-Cell Signaling and Interaction                               88                       70
  Cellular Development, Cell Death, Cellular Growth and Proliferation                                            26                       36
  Inflammatory Response, Organismal Injury and Abnormalities, Cellular Movement                                  24                       35
  Cellular Growth and Proliferation, Cellular Development, Cancer                                                24                       35
  Cell-To-Cell Signaling and Interaction, Inflammatory Response, Hematological System Development and Function   23                       34
  Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking                      23                       34

Networks significantly affected in RASFs compared to control SFs as determined by Ingenuity Pathway Analysis. The score is based on the p-value of the affected network. Networks with a score of 15 or greater were defined as significant.

###### 

Top networks affected by down-regulated genes/isoforms in rheumatoid arthritis synovial RNA

                                                                                                           **Down-regulated genes**   
  -------------------------------------------------------------------------------------------------------- -------------------------- -------
  Top Functions                                                                                            Score                      Genes
  Cellular Movement, Cell Death, Tissue Development                                                        35                         32
  Cellular Growth and Proliferation, Cellular Development, Hematological System Development and Function   29                         28
  Cell Cycle, Cellular Growth and Proliferation, Cell Death                                                27                         27
  Cellular Growth and Proliferation, Cell Cycle, Tissue Development                                        23                         24
  Hematological System Development and Function, Tissue Morphology, Tissue Development                     21                         23
                                                                                                           Down-Regulated Isoforms    
  Top Functions                                                                                            Score                      Genes
  Cellular Growth and Proliferation, Cell Death, Cellular Movement                                         45                         43
  DNA Replication, Recombination, and Repair, Cell Cycle, Hematological System Development and Function    28                         32
  Cellular Development, Cell Morphology, Cellular Assembly and Organization                                25                         30
  Cellular Growth and Proliferation, Tissue Morphology, Hematological System Development and Function      25                         30
  Cellular Growth and Proliferation, Cellular Movement, Embryonic Development                              24                         29
  Cell Death, Cellular Development, Hematological System Development and Function                          24                         29

Networks significantly affected in RASFs compared to control SFs as determined by Ingenuity Pathway Analysis. The score is based on the p-value of the affected network. Networks with a score of 15 or greater were defined as significant.

Canonical pathways analyses identified the pathways from the Ingenuity Pathways Analysis library of canonical pathways that were most significant to the data set. Genes with a two-fold or greater change in expression between SFs and RASFs and that were associated with a canonical pathway in Ingenuity's Knowledge Base were considered for the analyses. The top canonical pathways affected by up-regulated genes and isoforms (Table [11](#T11){ref-type="table"}) and the top canonical pathways affected by down-regulated genes and isoforms (Table [12](#T12){ref-type="table"}) are in agreement with the networks (Tables [9](#T9){ref-type="table"} and [10](#T10){ref-type="table"}) affected in RASFs. The top canonical pathways affected by up-regulated genes and isoforms (Table [11](#T11){ref-type="table"}) are consistent with the knowledge that B cells, T cells, and macrophage cells play key roles in the inflammatory response and are involved in the activation and proliferation of RASFs \[[@B3],[@B4],[@B7]\]. These findings are further supported by the analysis of the pathways affected by the down-regulated genes and isoforms (Table [12](#T12){ref-type="table"}). Dysregulation of the innate immune response and alterations in the number and types of cytokines and chemokines are well known features of RA \[[@B4],[@B7]\]. Altered cell cycle control of chromosomal replication and BRCA1 in DNA damage response, are in concordance with the hyperproliferation of synovial tissue and the corresponding decrease in apoptosis in RA \[[@B3],[@B38]\]. The identification of potential networks and pathways involved in arthritis may provide additional insights into the molecular and cellular mechanisms by which RASFs are involved in the pathogenesis of RA.

###### 

Top canonical pathways affected by up-regulated genes/isoforms in rheumatoid arthritis synovial RNA

                                                               **Up-regulated genes**    
  ------------------------------------------------------------ ------------------------ -------
  Canonical Pathway                                            p-value                  Ratio
  Antigen Presentation Pathway                                 0.000                    0.455
  Graft-versus-Host Disease Signaling                          0.000                    0.275
  Communication between Innate and Adaptive Immune Cells       0.000                    0.188
  Crosstalk between Dendritic Cells and Natural Killer Cells   0.000                    0.159
  Autoimmune Thyroid Disease Signaling                         0.000                    0.214
                                                               Up-regulated Isoforms     
  Canonical Pathway                                            p-value                  Ratio
  Atherosclerosis Signaling                                    0.001                    0.133
  Hepatic Fibrosis / Hepatic Stellate Cell Activation          0.001                    0.119
  Colorectal Cancer Metastasis Signaling                       0.010                    0.088
  Toll-like Receptor Signaling                                 0.011                    0.143
  FXR/RXR Activation                                           0.012                    0.114

Top canonical pathways significantly affected in RASFs compared to SFs as determined by Ingenuity Pathway Analysis. Pathways with a p-value less than 0.05 defined as significant.

###### 

Top canonical pathways affected by down-regulated genes/isoforms in rheumatoid arthritis synovial RNA

                                                 **Down-regulated genes**    
  ---------------------------------------------- -------------------------- -------
  Canonical Pathway                              p-value                    Ratio
  LXR/RXR Activation                             0.011                      0.057
  Atherosclerosis Signaling                      0.011                      0.057
  LPS/IL-1 Mediated Inhibition of RXR Function   0.017                      0.044
  Inhibition of Angiogenesis by TSP1             0.018                      0.083
  Phenylalanine Metabolism                       0.019                      0.086
                                                 Down-regulated Isoforms     
  Canonical Pathway                              p-value                    Ratio
  Role of BRCA1 in DNA Damage Response           0.002                      0.125
  Mitotic Roles of Polo-Like Kinase              0.002                      0.123
  Cardiac β-adrenergic Signaling                 0.004                      0.079
  Type I Diabetes Mellitus Signaling             0.005                      0.086
  Graft-versus-Host Disease Signaling            0.007                      0.125

Top canonical pathways significantly affected in RASFs compared to SFs as determined by Ingenuity Pathway Analysis. Pathways with a p-value less than 0.05 defined as significant.

Discussion
==========

In the present study, we performed a comprehensive transcriptome analysis of human SF RNA isolated from healthy controls and patients with RA using the Illumina RNA-seq technique. It has revealed a complete picture of differentially expressed genes and their isoforms in RASFs and provided a global transcriptional insight into the novel roles of synovial fibroblasts in the pathogenesis of rheumatoid arthritis.

For RNA-seq, we used the Illumina HiScanSQ instrument to perform a 2 × 101 paired end run for all of our samples. The advantage of a paired end run is that both reads contain long range positional information, allowing for highly precise alignment of reads. We calculated the number of differentially expressed genes between RNA from two control SF and two RASF samples. We obtained a mean value of 84,177,268 reads per sample, which meets the criteria for sufficient sequence coverage for transcriptome profiling \[[@B39]\]. Our mean rate of 86% total reads that map to the reference genome met quality standards of the RNA-seq technique \[[@B40]\]. The breadth of the RNA sequencing reads covering chromosome 1 for both the RASFs and normal SFs indicates quality RNA-seq runs (Figure [1](#F1){ref-type="fig"}). Therefore, we are confident that our RNA-seq data provides an objective, high quality profile of the transcriptome in human RASFs and normal SFs.

The aim of this study was to provide a global glean into the transcriptional regulation in RASFs, which may provide mechanistic insights into the pathogenesis of rheumatoid arthritis. The activation and subsequent proliferation of SFs by proinflammatory cytokines produced by cells from both the innate and the adaptive immune systems plays a critical role in the pathogenesis of RA \[[@B3]-[@B5]\]. The production of additional cytokines, chemokines and matrix-degrading enzymes by RASFs leads ultimately to the progressive destruction of the joint that is a hallmark feature of RA \[[@B5]-[@B7]\]. However, the complete repertoire of active molecules, networks and pathways of differentially expressed genes and their isoforms of RASFs in this process are not characterized fully. Our study is filling this gap of knowledge. With RNA-seq, we found that 214 genes were not expressed in RASFs while 682 genes were only expressed in RASFs (Table [2](#T2){ref-type="table"}). There are 122 up-regulated genes and 155 down-regulated genes by at least two-fold in RASFs compared to those in normal SFs. The majority of differentially expressed genes identified in this study (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} and Additional files [2](#S2){ref-type="supplementary-material"} and [4](#S4){ref-type="supplementary-material"}) have not been previously reported to be altered in RASFs compared to normal SFs. One notable prowess of RNA-seq is to identify and quantify the expression of different isoforms of a gene. Gene isoforms are generated by alternative splicing or alternative promoter usage. Regulation of different gene isoform expression is a central aspect of most normal and disease processes. In this study, we detected more than 20,000 expressed known isoforms and more than 40,000 expressed novel isoforms (Table [2](#T2){ref-type="table"}). Among them, there are 526 known isoforms which were not expressed in RASFs while 981 known isoforms were only expressed in RASFs. There are 343 up-regulated known isoforms and 262 down-regulated known isoforms by at least two-fold in RASFs compared to those in normal SFs. There are 105 novel isoforms which were not expressed in RASFs, while 152 novel isoforms were expressed only in RASFs. There are 561 up-regulated novel isoforms and 520 down-regulated novel isoforms by at least two-fold in RASFs compared to those in normal SFs. Network and canonical pathway analyses of differentially expressed genes and their known isoforms revealed that inflammatory response and cell death are represented strongly. Although these pathways have been predicted previously to correlate with RA, our study provided a more complete list of genes and isoforms involved in the inflammatory response and cell death pathways. We also identified other relevant novel networks and pathways, such as *Antigen Presentation Pathway*, *Atherosclerosis Signalling*, *LXR/RXR Activation*, and *Role of BRCA1 in DNA Damage Response*, whose dysregulation may each in part underlie their implication in the pathogenesis of RA.

Several microarray transcriptome analyses have been performed on RASFs \[[@B41]-[@B53]\]. The heterogeneous nature of RA and the different types of tissues used in these microarray studies leads to variations between the studies. The results from the present RNA-seq study both correlated and differed from previous microarray studies. The SFs used in our study were first isolated from synovial tissue either from healthy control donors or from patients with RA and cultured for two passages prior to RNA isolation. It should be noted, that this passage number is lower than what has been reported previously for gene profiling in SFs that have been cultured prior to RNA isolation. Del Rey et al. \[[@B43]\] and Masuda et al. \[[@B47]\] cultured SFs for 4 and 6 passages, respectively, before isolating RNA, while Haupl et al. \[[@B48]\] used immortalized SFs. The matrix metalloproteinases 1 (MMP1) and 3 (MMP3) are key players in the pathogenesis of RA \[[@B50]\]. MMP1 and MMP3 were up-regulated 816.2- fold and 215.6-fold, respectively, in our study. Microarray analyses of RA synovial tissue in three separate studies detected increased MMP1 expression of 63.1-fold \[[@B51]\], 31.0-fold \[[@B52]\], and 36.6-fold \[[@B53]\]. MMP3 expression was also increased 23.2-fold \[[@B52]\] and 18.7-fold \[[@B53]\] in these studies. Interleukin 1 beta (IL1B) and Interleukin 8 were up-regulated 3.2 and 9.3 fold, respectively, in RASFs from patients treated with prednisolone \[[@B48]\]. In the present study, IL1B was decreased by 25.3-fold and IL8 was down-regulated 9.5-fold. Collagen, Type III, alpha 1 (COL3A1) was increased 1.76 fold in a microarray study \[[@B44]\] compared to a 1.3-fold decrease in the present study. Keratin 7 (KRT7) was down-regulated 0.49 by microarray analysis \[[@B44]\] and 14.6-fold by RNA-seq. The results presented in our study correlate well with what has been previously reported in the literature. Of the top 40 differentially expressed genes (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}), 16 have been reported previously to be associated with RA (Additional file [3](#S3){ref-type="supplementary-material"}). Thus, we have identified 24 new potential gene targets among the genes listed in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} for further exploration. These findings are strengthened further by the ability of RNA-seq, as described above, to identify isoforms, both known and novel, that are expressed differentially in RA. With further improvements of next generation DNA sequencing techniques and further reductions of sequencing costs, it may be feasible to extend this study to analyze the transcriptomes of RASFs isolated from multiple patient samples at progressing stages of pathogenesis.

Conclusion
==========

In summary, our first complete transcriptome analysis of synovial fibroblast RNA from patients with rheumatoid arthritis using RNA-seq has provided important insights into the transcriptional regulation of gene expression in RASFs. Further in-depth, follow-up analyses using large patient populations will be necessary to validate the alterations in transcriptional regulation reported in this study and to provide the resources necessary to elucidate the molecular mechanisms underlying the role of SFs in the pathogenesis of RA.

Methods
=======

RNA sequencing
--------------

Human SF RNA from 2 healthy female donors and 2 adult female RA patients (Additional file [1](#S1){ref-type="supplementary-material"}) was purchased from Cell Applications, Inc. (San Diego, CA). SFs were first isolated from synovial tissue either from healthy control donors or from patients with RA and cultured for two passages prior to RNA isolation. Paired-end cDNA libraries were prepared for each sample and sequenced using the Illumina TruSeq RNA Sample Preparation Kit, as described previously \[[@B11],[@B12]\]. Briefly, the cDNA libraries were quantified using a Biotek EPOCH spectrophotometer and checked for quality and size using a Bio-Rad Experion DNA 1K chip. The four cDNA libraries were each diluted to 6 pM and spiked with 1% phiX control to improve base calling while sequencing. A 6 pM dilution of phiX control sample was also prepared for analysis. Following the Illumina cBot and HiSeq protocols, the four libraries and the phiX control underwent cluster generation on a HiSeq PE flow cell v3 and were then sequenced using a HiScanSQ (Illumina). A paired-end (2×101) run was performed using the SBS Kit (Illumina). Real-time analysis and base calling were performed using the HiSeq Control Software Version 1.4.5 (Illumina). The resulting basecalling (.bcl) files were converted to. FASTQ files using Illumina's CASAVA 1.8 software. The number of reads for each sample type was analyzed using the Student's t-test in SigmaPlot version 11.0 (Systat Software Inc., San Jose, CA). A p-value of below 0.05 was considered significant. The sequence data have been submitted to the NCBI Short Read Archive with accession number SRA048057.1.

Mapping of RNA-seq reads and transcript assembly and abundance estimation using Tuxedo Suite
--------------------------------------------------------------------------------------------

Paired-end fastq sequence reads for each sample were aligned to the UCSC *Homo sapiens* reference genome hg19 using TopHat v1.3.0 \[[@B54],[@B55]\] integrated with Bowtie v0.12.7 \[[@B56]\], as described previously \[[@B11],[@B12]\]. The resulting aligned reads were analyzed further by Cufflinks v1.0.3 \[[@B55],[@B57]\]. The aligned reads were assembled into transcripts, either with or without a reference genome, and the expression of those transcripts were reported in *Fragments Per Kilobase of exon per Million fragments mapped* (FPKM). Cuffdiff analysis was performed, with use of the reference genome, to determine differential expression of known isoforms between pooled RA patient samples and pooled control samples. To detect novel isoforms, Cufflinks was run without a reference genome. The RA and control transcript files were compared to the reference genome using Cuffcompare to filter out previously discovered transcripts. To test the differential expression of these novel isoforms, Cuffdiff analyses were performed using the combined transcript files as the reference genome. Cuffdiff analyses were performed two ways: comparing the RA patient transcripts to the control transcripts, using the RA patient transcripts as the reference genome; and comparing the RA patient transcripts to the control transcripts, using the control transcripts as the reference genome.

Visualization of mapped reads
-----------------------------

Aligned reads were visualized using a local copy of the Integrative Genomics Viewer (<http://www.broadinstitute.org/igv/>). The output files generated from TopHat were converted into files viewable in IGV by BEDTools \[[@B58]\] and then processed further by the "count" function in igvtools (included with the IGV software) to create an average alignment track viewable as a bar chart. The log~2~ of the frequency of the reads was plotted to better visualize the extensive range of the read coverage. Individual gene views were created by first merging the TopHat output files from the RA and control samples into two files using SAMTools \[[@B59]\]. These merged files were processed in the same way as above with the "count" function in igvtools. The raw frequency of the reads was visualized in this case.

Automated literature search
---------------------------

Multiplex literature mining analysis was conducted with PubMatrix, \[[@B22]\] as described previously \[[@B60]\]. We restricted our search to human symbols approved by HUGO Gene Nomenclature Committee (HGNC) for the top 10 genes and isoforms for each category. Terms "rheumatoid arthritis", "osteoarthritis", "arthritis" and "disease" were used for cross-referencing candidate genes.

Functional analysis of differentially expressed gene lists using ingenuity pathway analysis
-------------------------------------------------------------------------------------------

The differentially expressed gene lists were submitted to Ingenuity Pathway Analysis (IPA) v9.0-3211 (Ingenuity Systems, Inc., Redwood City, CA). Genes with a two-fold or greater change in expression between the RA group and the control group were used. The settings for the core analysis were as follows: Ingenuity Knowledge Base; Endogenous Chemicals not included; Direct and Indirect relationships; molecules per pathway: 70; and networks per analysis: 25.
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